CITY OF INDUSTRY, CA--(Marketwired - Oct 27, 2016) - Prolacta Bioscience®, the nation's leading provider of human milk-based neonatal nutritional products, announced today it will host a symposium during the 32nd annual National Association of Neonatal Nurses (NANN) Educational Conference in Palm Springs, Calif on Oct. 29, 2016.

The symposium, titled, "Compelling Evidence for Nursing Advocates for an Exclusive Human Milk Diet (EHMD) in the NICU," will explore the clinical and economic benefits of an EHMD for premature infants in the NICU and their future health outcomes. It will also include insights from a preemie-parent perspective.

Speakers and topics during the symposium include:

  • Sergio G. Golombek, M.D., M.P.H., F.A.A.P. - M. Fareri Children's Hospital: Clinical and economic outcomes for the use of an EHMD for less than 1,250g birthweight infants

  • Olivia Myers, R.D., C.S.P., I.B.C.L.C. - Lucile Packard Children's Hospital: Preterm nutrition - Recommendations for optimal human milk-based human milk fortification

  • Terry S. Johnson, A.P.N., N.N.P.-B.C., C.L.E.C., A.S.P.P.S, M.N., C.E. - Prolacta Bioscience: Immunological benefits of human milk - The role of human milk in neonatal immune system development

  • Emily Million, R.N. - Prolacta Bioscience: Dual perspective on the importance of human milk nutrition in the NICU and the importance of parent advocacy and empowerment

"We're proud to be at this year's National Association of Neonatal Nurses Educational Conference as we bring together the clinical and parent perspectives on an exclusive human milk diet for premature infants in the NICU," said Scott Elster, president and CEO of Prolacta Bioscience. "Through our symposium, we are creating greater advocacy and education around the importance of human milk-based nutrition among neonatal nurses, who play a vital role in the care of critically ill preemies."

For additional information on Prolacta's symposium during NANN, visit

About Prolacta Bioscience
Prolacta Bioscience, Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. The company pioneered the development of human milk-based neonatal nutritional products to meet the needs of critically ill, premature infants in the NICU. Prolacta leads the industry in the quality and safety of nutritional products made from donor breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk. For more information, please visit